Immunomodulatory effects of H.P. Acthar gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus

Lupus

Volumn 23, Issue 8, 2014, Pages 802-812

  Decker, D A ^a   Grant, C ^b   Oh, L ^a   Becker, P M ^a   Young, D ^a   Jordan, S ^a  

^a Questcor Pharmaceuticals Inc   (United States)

^b Biomedical Research Models Inc   (United States)

Author keywords

ACTH; Acthar Gel; B cells; Melanocortin peptides; NZB W F1; Systemic lupus erythematosus

Indexed keywords

ACTHAR GEL H.P; CORTICOTROPIN; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PLACEBO; PREDNISOLONE SODIUM SUCCINATE; UNCLASSIFIED DRUG; GEL; HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DISEASE SEVERITY; GERMINAL CENTER; GLOMERULOPATHY; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARY FOLLICLE CELL; PRIORITY JOURNAL; PROTEINURIA; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; WEIGHT REDUCTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; GEL; IMMUNOLOGY; NEW ZEALAND BLACK MOUSE; PHYSIOLOGY;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GELS; HORMONES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB;

EID: 84903549365     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314531840     Document Type: Article

References (51)

1. Dorner T, Giesecke C, Lipsky PE. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011; 13: 243.
2. Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther 2008; 10: 218.
3. William J, Euler C, Primarolo N, et al. B cell tolerance checkpoints that restrict pathways of antigen-driven differentiation. J Immunol 2006; 176: 2142-2151.
4. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exper Med 2005; 201: 703-711.
5. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007; 65: 182-186.
6. Marian V, Anolik JH. Treatment targets in systemic lupus erythematosus: Biology and clinical perspective. Arthritis Res Ther 2012; 14(Suppl. 4): S3.
7. Ramanujam M, Bethunaickan R, Huang W, et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010; 62: 1457-1468.
8. Schioth HB, Muceniece R, Larsson M, et al. The melanocortin 1, 3, 4 or 5 receptors do not have a binding epitope for ACTH beyond the sequence of alpha-MSH. J Endocrinol 1997; 155: 73-78.
9. Catania A, Gatti S, Colombo G, et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56: 1-29.
10. Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. ScientificWorldJournal 2010; 10: 1840-1853.
11. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH). Discov Med 2011; 12: 91-96.
12. Cui HS, Hayasaka S, Zhang XY, et al. Effect of alpha- melanocytestimulating hormone on interleukin 8 and monocyte chemotactic protein 1 expression in a human retinal pigment epithelial cell line. Ophthalmic Res 2005; 37: 279-288.
13. Brod SA, Hood ZM. Ingested (oral) ACTH inhibits EAE. J Neuroimmunol 2011; 232: 131-135.
14. Chiao H, Kohda Y, McLeroy P, et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99: 1165-1172.
15. Lee SY, Jo SK, Cho WY, et al. The effect of alpha-melanocytestimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporine A nephrotoxicity. Transplantation 2004; 78: 1756-1764.
16. Si J, Ge Y, Zhuang S, et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int 2013; 83: 635-646.
17. Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010; 21: 1290-1298.
18. Bomback AS, Canetta PA, Beck Jr LH, et al. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial. Am J Nephrol 2012; 36: 58-67.
19. Cohen H, Cadman EF. The natural history of lupus erythematosus and its modification by cortisone and corticotrophin (A.C.T.H.). Lancet 1953; 265: 306-312.
20. Carey RA, Harvey AM, Howard JE. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and peri-arteritis nodosa. Bull Johns Hopkins Hosp 1950; 87: 425-460.
21. Takahashi T, Strober S. Natural killer T cells and innate immune B cells from lupus-prone NZB/W mice interact to generate IgM and IgG autoantibodies. Eur J Immunol 2008; 38: 156-165.
22. Eilat D, Wabl M. B cell tolerance and positive selection in lupus. J Immunol 2012; 189: 503-509.
23. Perry D, Sang A, Yin Y, et al. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011; 2716942011.
24. Lambert PH, Dixon FJ. Pathogenesis of the glomerulonephritis of NZB/W mice. J Exper Med 1968; 127: 507-522.
25. Hahn BH, Knotts L, Ng M, et al. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice. Arthritis Rheum 1975; 18: 145-152.
26. Jacobi AM, Diamond B. Balancing diversity and tolerance: Lessons from patients with systemic lupus erythematosus. J Exper Med 2005; 202: 341-344.
27. Arnason BG, Berkovich R, Catania A, et al. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 2013; 19: 130-136.
28. Moustafa M, Szabo M, Ghanem GE, et al. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol 2002; 119: 1244-1253.
29. Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor- Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524-3534.
30. Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006; 116: 724-734.
31. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 2009; 9: 767-777.
32. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009; 183: 3561-3567.
33. Woo YJ, Yoon BY, Jhun JY, et al. Regulation of B cell activating factor (BAFF) receptor expression by NF-KappaB signaling in rheumatoid arthritis B cells. Exp Mol Med 2011; 43: 350-357.
34. Pranzatelli MR, Tate ED, Hoefgen ER, et al. Therapeutic downregulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine 2008; 44: 26-32.
35. Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: Diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009; 45: 144-158.
36. Pillai S, Mattoo H, Cariappa A. B cells and autoimmunity. Curr Opin Immunol 2011; 23: 721-731.
37. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2: 323-335.
38. Duan B, Croker BP, Morel L. Lupus resistance is associated with marginal zone abnormalities in an NZM murine model. Lab Invest 2007; 87: 14-28.
39. Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: Efficacy and resistance. J Immunol 2007; 179: 3351-3361.
40. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
41. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2443-2457.
42. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009; 11: 247.
43. Johnson HM, Smith EM, Torres BA, et al. Regulation of the in vitro antibody response by neuroendocrine hormones. Proc Natl Acad Sci U S A 1982; 79: 4171-4174.
44. Clarke BL, Bost KL. Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J Immunol 1989; 143: 464-469.
45. Stirzaker RA, Biswas PS, Gupta S, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012; 21: 656-661.
46. Schiffer L, Sinha J, Wang X, et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003; 171: 489-497.
47. Hughes GC, Martin D, Zhang K, et al. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice. Arthritis Rheum 2009; 60: 1775-1784.
48. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 3247-3253.
49. Schiffer L, Bethunaickan R, Ramanujam M, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008; 180: 1938-1947.
50. Bethunaickan R, Berthier CC, Ramanujam M, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 2011; 186: 4994-5003.
51. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am 2012; 41: 595-611.